Biomerieux. – AGM 30 June 2020
ITEM 4: This resolution seeks shareholder approval of the allocation of income and
dividend payment. With the publication of the 2019 financial results, the Company had
initially recommended a dividend of €0.38 per share for a total payout of around €45
million. To meet the unprecedented challenges of solidarity and responsibility imposed
by the current situation, the Board of Directors exceptionally recommends reducing the
dividend that will be paid on 16 July 2020 to €0.19 per share. The remainder of the
originally planned total payout, representing around €22 million, will be used for
philanthropy with the aim of supporting solidarity actions. We recommend to APPOVE.
ITEM 9 and ITEM 10: The Company seeks shareholder approval of the remuneration
Policy of the Chairman CEO and Chief Operating Officer for 2020. The overall
remuneration policies remain unchanged. The company discloses the fixed remuneration
for 2020 which is satisfactory. The amounts remain under control. Accordingly, we
recommend to APPROVE.
Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.